MX2022014887A - Compuestos derivados de heteroarilo, y usos de los mismos. - Google Patents

Compuestos derivados de heteroarilo, y usos de los mismos.

Info

Publication number
MX2022014887A
MX2022014887A MX2022014887A MX2022014887A MX2022014887A MX 2022014887 A MX2022014887 A MX 2022014887A MX 2022014887 A MX2022014887 A MX 2022014887A MX 2022014887 A MX2022014887 A MX 2022014887A MX 2022014887 A MX2022014887 A MX 2022014887A
Authority
MX
Mexico
Prior art keywords
heteroaryl derivative
derivative compound
her2
present
egfr
Prior art date
Application number
MX2022014887A
Other languages
English (en)
Spanish (es)
Inventor
Nam Doo Kim
Jung Beom Son
Hyeon Ho Jeon
Hee Sun Ryu
Youn Ho Lee
Seon Ah Hwang
Hong Ryul Jung
Sung Hwan Kim
In Seob Shim
Woo Mi Do
Young Yi Lee
Original Assignee
Voronoibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoibio Inc filed Critical Voronoibio Inc
Publication of MX2022014887A publication Critical patent/MX2022014887A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022014887A 2021-05-17 2022-05-16 Compuestos derivados de heteroarilo, y usos de los mismos. MX2022014887A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210063733 2021-05-17
PCT/KR2022/006994 WO2022245085A1 (ko) 2021-05-17 2022-05-16 헤테로아릴 유도체 화합물 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2022014887A true MX2022014887A (es) 2023-01-11

Family

ID=84141801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014887A MX2022014887A (es) 2021-05-17 2022-05-16 Compuestos derivados de heteroarilo, y usos de los mismos.

Country Status (12)

Country Link
US (3) US12037330B2 (cg-RX-API-DMAC7.html)
EP (1) EP4342895A4 (cg-RX-API-DMAC7.html)
JP (1) JP7896880B2 (cg-RX-API-DMAC7.html)
KR (2) KR102607051B1 (cg-RX-API-DMAC7.html)
CN (1) CN115667251A (cg-RX-API-DMAC7.html)
AU (1) AU2022271388A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180295A1 (cg-RX-API-DMAC7.html)
IL (1) IL298474A (cg-RX-API-DMAC7.html)
MX (1) MX2022014887A (cg-RX-API-DMAC7.html)
TW (1) TWI869674B (cg-RX-API-DMAC7.html)
WO (1) WO2022245085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
JP2020526499A (ja) 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
US11440899B2 (en) 2017-10-17 2022-09-13 Merck Patent Gmbh Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
JP7109013B2 (ja) 2019-03-19 2022-07-29 ボロノイ インコーポレイテッド ヘテロアリール誘導体、ヘテロアリール誘導体の生成方法、およびヘテロアリール誘導体を有効成分として含む医薬組成物
WO2020235902A1 (ko) * 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
US20230322753A1 (en) 2020-09-18 2023-10-12 Voronoi Inc. Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient
KR20220085735A (ko) 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
US20240262815A1 (en) 2021-05-07 2024-08-08 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Also Published As

Publication number Publication date
US20240317730A1 (en) 2024-09-26
US12534457B2 (en) 2026-01-27
TWI869674B (zh) 2025-01-11
TW202310845A (zh) 2023-03-16
US20240166640A1 (en) 2024-05-23
IL298474A (en) 2023-01-01
CN115667251A (zh) 2023-01-31
US20240025888A1 (en) 2024-01-25
AU2022271388A1 (en) 2022-12-01
US12037330B2 (en) 2024-07-16
KR20220156453A (ko) 2022-11-25
JP7896880B2 (ja) 2026-07-29
EP4342895A4 (en) 2025-09-10
CA3180295A1 (en) 2022-11-24
BR112022024068A2 (pt) 2023-12-05
EP4342895A1 (en) 2024-03-27
KR20230163335A (ko) 2023-11-30
KR102607051B1 (ko) 2023-11-30
US12528799B2 (en) 2026-01-20
WO2022245085A1 (ko) 2022-11-24
JP2024519626A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
PH12023550119A1 (en) Egfr inhibitor
PH12020551305A1 (en) Pharmaceutical Compounds
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
PH12019501685A1 (en) Quinazone compound
EP4374858A3 (en) Benzimidazolone derived inhibitors of bcl6
EP4365179A3 (en) Novel rapamycin derivatives
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
ZA201902335B (en) Pharmaceutical compounds
EP4620531A3 (en) Bicyclic heteroaryl compounds and uses thereof
MY199511A (en) Novel condensed pyrimidine compound or salt thereof
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX380901B (es) Compuestos inhibidores de parg.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
EA201991253A1 (ru) Бензодиазолиевые соединения в качестве ингибиторов enac
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
EP4643954A3 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
GEP20267853B (en) Bicyclic heteroaromatic inhibitors of klk5
GEAP202415862A (en) Alcohol derivatives as kv7 potassium channel openers
SG11201803867TA (en) Sodium channel blocker
BR112022024068A2 (pt) Compostos de derivado de heteroarila e usos dos mesmos